Evoke Pharma, Inc. expected to return to positive sequential revenue growth in 2023 as the sales mix returns to levels saw in the first 3 quarters of 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.47 USD | 0.00% | -2.08% | -55.25% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.25% | 3.98M | |
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+16.06% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B |
- Stock Market
- Equities
- EVOK Stock
- News Evoke Pharma, Inc.
- Evoke Pharma, Inc. Provides Revenue Guidance for 2023